- Home
- URGN vs PVBC Comparison
URGN vs PVBC Comparison
Compare URGN & PVBC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- URGN
- PVBC
- Stock Information
- Founded
- URGN 2004
- PVBC 1913
- Country
- URGN United States
- PVBC United States
- Employees
- URGN N/A
- PVBC N/A
- Industry
- URGN Biotechnology: Pharmaceutical Preparations
- PVBC Major Banks
- Sector
- URGN Health Care
- PVBC Finance
- Exchange
- URGN Nasdaq
- PVBC Nasdaq
- Market Cap
- URGN 181.2M
- PVBC 202.6M
- IPO Year
- URGN 2017
- PVBC 2015
- Fundamental
- Price
- URGN $13.84
- PVBC $12.77
- Analyst Decision
- URGN Strong Buy
- PVBC Hold
- Analyst Count
- URGN 8
- PVBC 1
- Target Price
- URGN $29.00
- PVBC $12.50
- AVG Volume (30 Days)
- URGN 4.3M
- PVBC 311.8K
- Earning Date
- URGN 08-12-2025
- PVBC 07-28-2025
- Dividend Yield
- URGN N/A
- PVBC N/A
- EPS Growth
- URGN N/A
- PVBC N/A
- EPS
- URGN N/A
- PVBC 0.26
- Revenue
- URGN $91,871,000.00
- PVBC $50,244,000.00
- Revenue This Year
- URGN $36.65
- PVBC $9.73
- Revenue Next Year
- URGN $88.35
- PVBC $4.87
- P/E Ratio
- URGN N/A
- PVBC $48.81
- Revenue Growth
- URGN 8.98
- PVBC N/A
- 52 Week Low
- URGN $3.42
- PVBC $9.67
- 52 Week High
- URGN $18.15
- PVBC $12.96
- Technical
- Relative Strength Index (RSI)
- URGN 64.90
- PVBC 80.02
- Support Level
- URGN $13.26
- PVBC $12.60
- Resistance Level
- URGN $13.94
- PVBC $12.83
- Average True Range (ATR)
- URGN 0.91
- PVBC 0.17
- MACD
- URGN -0.08
- PVBC 0.05
- Stochastic Oscillator
- URGN 44.44
- PVBC 94.87
About URGN UroGen Pharma Ltd.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.
About PVBC Provident Bancorp Inc. (MD)
Provident Bancorp Inc provides a range of banking products and services to small and medium-sized commercial customers. It attracts deposits from the general public and uses those funds to originate loans, commercial real estate, construction and land, and commercial business loans, and to invest in securities. The company lending activities include providing commercial real estate loans, multi-family residential real estate loans, commercial business loans, construction and land development loans, one-to four-family residential loans, home equity loans & lines of credit, and consumer loans.